癌症靶向治疗的最新进展。
Recent progress in targeting cancer.
作者信息
Demidenko Zoya N, McCubrey James A
机构信息
Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
出版信息
Aging (Albany NY). 2011 Dec;3(12):1154-62. doi: 10.18632/aging.100421.
Abstract
In recent years, numerous new targets have been identified and new experimental therapeutics have been developed. Importantly, existing non-cancer drugs found novel use in cancer therapy. And even more importantly, new original therapeutic strategies to increase potency, selectivity and decrease detrimental side effects have been evaluated. Here we review some recent advances in targeting cancer.
摘要
近年来，已确定了众多新靶点，并开发了新的实验性治疗方法。重要的是，现有的非癌症药物在癌症治疗中发现了新用途。更重要的是，已评估了提高效力、选择性并减少有害副作用的新的原创治疗策略。在此，我们综述靶向癌症方面的一些最新进展。
相似文献
1
Recent progress in targeting cancer.
Aging (Albany NY). 2011 Dec;3(12):1154-62. doi: 10.18632/aging.100421.
2
Targeting cancer with kinase inhibitors.
J Clin Invest. 2015 May;125(5):1780-9. doi: 10.1172/JCI76094. Epub 2015 May 1.
3
NUPR1 and its potential role in cancer and pathological conditions (Review).
Int J Oncol. 2021 May;58(5). doi: 10.3892/ijo.2021.5201. Epub 2021 Mar 24.
4
Back to the Future: Therapeutic Targeting of Cancer Cell Metabolism.
SLAS Discov. 2017 Apr;22(4):333-337. doi: 10.1177/2472555217691265.
5
Aberrant lipid metabolism in cancer cells - the role of oncolipid-activated signaling.
FEBS J. 2018 Feb;285(3):432-443. doi: 10.1111/febs.14281. Epub 2017 Oct 23.
6
[Signal transduction and its targeting from the cancer molecular genetic platform: applications and perspectives in pulmonary pathology].
Ann Pathol. 2011 Nov;31(5 Suppl):S40-2. doi: 10.1016/j.annpat.2011.08.020. Epub 2011 Oct 11.
7
Exploring Proteomic Drug Targets, Therapeutic Strategies and Protein - Protein Interactions in Cancer: Mechanistic View.
Curr Cancer Drug Targets. 2019;19(6):430-448. doi: 10.2174/1568009618666180803104631.
8
Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics.
Drug Resist Updat. 2016 Sep;28:65-81. doi: 10.1016/j.drup.2016.07.001. Epub 2016 Jul 16.
9
Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and MicroRNA as New Treatment Candidates.
Molecules. 2018 Mar 29;23(4):787. doi: 10.3390/molecules23040787.
10
Clinical development of antisense oligonucleotides as anti-cancer therapeutics.
Methods Mol Med. 2003;75:621-36. doi: 10.1385/1-59259-324-0:621.
引用本文的文献
1
Profiling of Human Molecular Pathways Affected by Retrotransposons at the Level of Regulation by Transcription Factor Proteins.
Front Immunol. 2018 Jan 30;9:30. doi: 10.3389/fimmu.2018.00030. eCollection 2018.
2
mTOR kinase inhibitor pp242 causes mitophagy terminated by apoptotic cell death in E1A-Ras transformed cells.
Oncotarget. 2015 Dec 29;6(42):44905-26. doi: 10.18632/oncotarget.6457.
3
Advances in targeting signal transduction pathways.
Oncotarget. 2012 Dec;3(12):1505-21. doi: 10.18632/oncotarget.802.
4
NRF2 and p53: Januses in cancer?
Oncotarget. 2012 Nov;3(11):1272-83. doi: 10.18632/oncotarget.754.
5
p63 the guardian of human reproduction.
Cell Cycle. 2012 Dec 15;11(24):4545-51. doi: 10.4161/cc.22819. Epub 2012 Nov 19.
6
Persistent DNA damage caused by low levels of mitomycin C induces irreversible cell senescence.
Cell Cycle. 2012 Aug 15;11(16):3132-40. doi: 10.4161/cc.21506. Epub 2012 Aug 8.
7
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon.
Oncotarget. 2012 Mar;3(3):236-60. doi: 10.18632/oncotarget.466.
本文引用的文献
1
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.
Cancer Cell. 2011 Dec 13;20(6):715-27. doi: 10.1016/j.ccr.2011.11.004.
2
Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.
Ann Oncol. 2012 Jul;23(7):1771-80. doi: 10.1093/annonc/mdr534. Epub 2011 Nov 22.
3
A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells.
Cancer Cell. 2011 Nov 15;20(5):620-34. doi: 10.1016/j.ccr.2011.10.001.
4
Tumor angiogenesis: molecular pathways and therapeutic targets.
Nat Med. 2011 Nov 7;17(11):1359-70. doi: 10.1038/nm.2537.
5
Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules.
Nat Med. 2011 Nov 6;17(12):1685-91. doi: 10.1038/nm.2554.
6
Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
Nat Med. 2011 Nov 6;17(12):1636-40. doi: 10.1038/nm.2536.
7
GHRH antagonist MZ-5-156 increases the expression of AMPK in A549 lung cancer cells.
Cell Cycle. 2011 Nov 1;10(21):3714-8. doi: 10.4161/cc.10.21.17904.
8
Rapamycin passes the torch: a new generation of mTOR inhibitors.
Nat Rev Drug Discov. 2011 Oct 31;10(11):868-80. doi: 10.1038/nrd3531.
9
The metabolic regulator ERRα, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer.
Cancer Cell. 2011 Oct 18;20(4):500-10. doi: 10.1016/j.ccr.2011.08.023.
10
Expression of FACT in mammalian tissues suggests its role in maintaining of undifferentiated state of cells.
Oncotarget. 2011 Oct;2(10):783-96. doi: 10.18632/oncotarget.340.
Zotero 插件